ResearchMoz added Latest Research Report titled " Global Post Menopausal Vaginal Atrophy Drugs Market 2016-2020 " to it's Large Report database.
About Post-Menopausal Vaginal Atrophy Drugs
Vaginal atrophy also known as atrophic vaginitis is defined as a decrease in the production of estrogen after menopause, leading to thinning, drying, and reduced elasticity of the vaginal tissues. Up to 40% of post-menopausal women have symptoms of atrophic vaginitis. It typically affects women in the age group of 45-55 years. PVA result in symptoms such as itching, burning, dryness, and dyspareunia. Topical preparations such as hormone replacement therapy (HRT) and estrogen creams are used to treat PVA.
Technavios analysts forecast the global PVA drugs market to grow at a CAGR of 7.13% during the period 2016-2020.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=711490
Covered in this report
The report covers the present scenario and the growth prospects of the global PVA drugs market for 2015-2020. To calculate the market size, the report considers revenue generated from the sales of drugs (creams, tablets, patches, and rings) used to treat PVA.
The market is divided into the following segments based on geography:
Americas
EMEA
APAC
Technavio's report, Global Post-Menopausal Vaginal Atrophy Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html
Table of Content
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
Assumptions
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
Key buying criteria
PART 05: Overview: Vaginal atrophy
Symptoms
Causes
Pathophysiology
Diagnosis
Treatment
Epidemiology
PART 06: Branded drug profiles
Activella
Enjuvia
Estrace
Femring
Premarin
Osphena
Vagifem
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
About Post-Menopausal Vaginal Atrophy Drugs
Vaginal atrophy also known as atrophic vaginitis is defined as a decrease in the production of estrogen after menopause, leading to thinning, drying, and reduced elasticity of the vaginal tissues. Up to 40% of post-menopausal women have symptoms of atrophic vaginitis. It typically affects women in the age group of 45-55 years. PVA result in symptoms such as itching, burning, dryness, and dyspareunia. Topical preparations such as hormone replacement therapy (HRT) and estrogen creams are used to treat PVA.
Technavios analysts forecast the global PVA drugs market to grow at a CAGR of 7.13% during the period 2016-2020.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=711490
Covered in this report
The report covers the present scenario and the growth prospects of the global PVA drugs market for 2015-2020. To calculate the market size, the report considers revenue generated from the sales of drugs (creams, tablets, patches, and rings) used to treat PVA.
The market is divided into the following segments based on geography:
Americas
EMEA
APAC
Technavio's report, Global Post-Menopausal Vaginal Atrophy Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html
Table of Content
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
Assumptions
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
Key buying criteria
PART 05: Overview: Vaginal atrophy
Symptoms
Causes
Pathophysiology
Diagnosis
Treatment
Epidemiology
PART 06: Branded drug profiles
Activella
Enjuvia
Estrace
Femring
Premarin
Osphena
Vagifem
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
No comments:
Post a Comment